<?xml version="1.0" encoding="utf-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>IJIRCSTJournal</PublisherName>
      <JournalTitle>International Journal of Innovative Research in Computer Science and Technology</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 10 Issue 2</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Management</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>March - April 2022</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>26</Day>
      </PubDate>
      <ArticleType>Computer Sciences</ArticleType>
      <ArticleTitle>Recommendations for the Development and Improvement of Immunoassays for the Detection of Host Antibodies to Biotechnology Goods</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>43</FirstPage>
      <LastPage>46</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Mr Davinder Singh</FirstName>          
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
             
        </Author>
      </AuthorList>
      <DOI> https://doi.org/10.55524/ijircst.2022.10.2.8</DOI>
      <Abstract>The majority of biopharmaceutical treatments generate some amount Allergic reaction to a foodstuff. In some instances, an immune reaction may have had serious consequences. And/or a loss of effectiveness. As a result, doctors, producers, and regulatory authorities are concerned about the immunogenicity of therapeutic proteins. To determine the immunogenicity of a substance, Antibody responses must be detected, quantified, and characterized appropriately for these compounds. Inadequately Antibody tests that have been poorly developed have hampered project planning or thread before licensed Agreements. Based on the experts&amp;#39; knowledge, this document includes scientific recommendations for the development of pro-government monoclonal confirmatory testing for developmental or laboratory tests. Although the emphasis of just this article is on immunoassay construct, we also provide factual background information on the major assay effectiveness standards that are set in order to develop an effective experiment. Articles regarding trial requirements, as well as those found in government recommendations, are given in this study.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Assays, Antibody, Immunogenicity, Matrix, Molecule.</Keywords>
      <URLs>
        <Abstract>https://ijircst.org/abstract.php?article_id=838</Abstract>
      </URLs>      
    </Journal>
  </Article>
</ArticleSet>